NEW WEBSITE We would like to invite you to a sneak peak of our new website before it goes live. Visit the new site

Leandro Cerchietti, October 13

SciLifeLab The Svedberg seminar series

Monday, October 13

Leandro Cerchietti

Weill Cornell Medical College, Cornell University, New York City, New York, USA.

Dr. Leandro Cerchietti is a Raymond and Beverly Sackler Scholar and Assistant Professor at Weill Cornell Medical College, Cornell University, New York City, New York, USA.

Epigenetic basis and targeted therapy of B-cell lymphomas

Epigenetic regulation is a fundamental process required by all cell types. Epigenetic marks form a biochemical language required to encode cellular phenotypes. Proteins that write, read and erase epigenetic instructions and the transcription factors that guide them play fundamental roles in normal B-cell development and lymphomagenesis. Aberrant epigenetic patterning, and somatic mutation of epigenetic modifier proteins, are hallmarks of B-cell lymphomas. In germinal center B-cells histone marks are dynamically controlled by transcription factors such as BCL6, and chromatin modifying proteins such as EZH2, MLL4 and CBP/EP300, which are perturbed in lymphomas. Lymphomas exhibit profound perturbations in cytosine methylation. DNA methylation heterogeneity occurs naturally in GC B-cells and is quite extreme in lymphomas, where it is linked to poor clinical outcome. Reversal of aberrant cytosine methylation in key pathways can induce chemo-sensitization of DLBCLs. Epigenetic therapy using inhibitors of BCL6, EZH2 and DNMTs is a promising new approach in lymphoma therapeutics.

Host: Richard Rosenqvist Brandell